JP2022525013A5 - - Google Patents
Info
- Publication number
- JP2022525013A5 JP2022525013A5 JP2021552772A JP2021552772A JP2022525013A5 JP 2022525013 A5 JP2022525013 A5 JP 2022525013A5 JP 2021552772 A JP2021552772 A JP 2021552772A JP 2021552772 A JP2021552772 A JP 2021552772A JP 2022525013 A5 JP2022525013 A5 JP 2022525013A5
- Authority
- JP
- Japan
- Prior art keywords
- composition according
- pharmaceutically acceptable
- acceptable salt
- active against
- additional agents
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962814316P | 2019-03-06 | 2019-03-06 | |
| US62/814,316 | 2019-03-06 | ||
| PCT/IB2020/051878 WO2020178767A1 (en) | 2019-03-06 | 2020-03-04 | Compounds useful in hiv therapy |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022525013A JP2022525013A (ja) | 2022-05-11 |
| JP2022525013A5 true JP2022525013A5 (https=) | 2024-07-16 |
Family
ID=69845479
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021552772A Ceased JP2022525013A (ja) | 2019-03-06 | 2020-03-04 | Ｈｉｖ療法において有用な化合物 |
Country Status (22)
| Country | Link |
|---|---|
| US (4) | US12240853B2 (https=) |
| EP (1) | EP3934760A1 (https=) |
| JP (1) | JP2022525013A (https=) |
| KR (1) | KR20210136052A (https=) |
| CN (1) | CN113811360A (https=) |
| AR (1) | AR118240A1 (https=) |
| AU (1) | AU2020231934B2 (https=) |
| BR (1) | BR112021017604A2 (https=) |
| CA (1) | CA3132112A1 (https=) |
| CL (1) | CL2021002309A1 (https=) |
| CO (1) | CO2021012579A2 (https=) |
| CR (1) | CR20210460A (https=) |
| EA (1) | EA202192433A1 (https=) |
| IL (1) | IL285894A (https=) |
| MA (1) | MA55200A (https=) |
| MX (1) | MX2021010700A (https=) |
| PE (1) | PE20212089A1 (https=) |
| PH (1) | PH12021500034A1 (https=) |
| SG (1) | SG11202109253SA (https=) |
| TW (1) | TW202102233A (https=) |
| WO (1) | WO2020178767A1 (https=) |
| ZA (1) | ZA202106096B (https=) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3146679A1 (en) * | 2019-07-27 | 2021-02-04 | Brii Biosciences, Inc. | Adenosine derivative and pharmaceutical composition comprising the same |
| KR20220066303A (ko) | 2019-09-11 | 2022-05-24 | 더 스크립스 리서치 인스티튜트 | 항바이러스 전구약물 및 이의 약제학적 조성물 |
| JP7703538B2 (ja) * | 2019-12-09 | 2025-07-07 | ヴィーブ、ヘルスケア、カンパニー | カボテグラビルを含んでなる医薬組成物 |
| WO2021188959A1 (en) * | 2020-03-20 | 2021-09-23 | Gilead Sciences, Inc. | Prodrugs of 4'-c-substituted-2-halo-2'-deoxyadenosine nucleosides and methods of making and using the same |
| KR102918401B1 (ko) * | 2020-12-30 | 2026-01-26 | 서던 유니버시티 오브 사이언스 앤드 테크놀로지 | 코로나 바이러스 감염을 치료하기 위한 방법 및 변형된 뉴클레오사이드 |
| EP4281081A4 (en) * | 2021-01-25 | 2025-05-14 | Brii Biosciences, Inc. | ADENOSINE DERIVATIVE AND PHARMACEUTICAL COMPOSITION THEREOF |
| EP4281083A4 (en) * | 2021-01-25 | 2025-01-01 | Brii Biosciences, Inc. | COMBINATION THERAPY FOR HIV WITH ADENOSINE DERIVATIVE AND CAPSID INHIBITORS |
| WO2022182604A1 (en) * | 2021-02-23 | 2022-09-01 | Viiv Healthcare Company | Compounds useful in hiv treatment |
| CR20250310A (es) * | 2023-01-30 | 2025-08-25 | Merck Sharp & Dohme Llc | Profármacos de inhibidores de la transcriptasa inversa de nucleósidos sustituidos en 4' |
| AU2024353051A1 (en) | 2023-09-27 | 2026-03-12 | ViiV Healthcare UK (No.3) Limited | Pharmaceutical compositions |
| AU2023466962A1 (en) | 2023-09-27 | 2026-03-12 | ViiV Healthcare UK (No.3) Limited | Pharmaceutical composition of cabotegravir |
Family Cites Families (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB427857A (en) | 1934-08-02 | 1935-05-01 | Newsum Sons & Company Ltd H | A new or improved system of construction for skeleton structures, particularly vehicle body frames and door frames |
| US4107288A (en) | 1974-09-18 | 1978-08-15 | Pharmaceutical Society Of Victoria | Injectable compositions, nanoparticles useful therein, and process of manufacturing same |
| US5145684A (en) | 1991-01-25 | 1992-09-08 | Sterling Drug Inc. | Surface modified drug nanoparticles |
| ATE250622T1 (de) | 1999-05-12 | 2003-10-15 | Yamasa Corp | 4'-c-ethynyl-pyrimidine nukleoside |
| EP1378509A4 (en) | 2001-03-19 | 2009-03-25 | Ono Pharmaceutical Co | DRUGS WITH TRIAZASPIRO ç5.5] UNDECANDERIVATES AS ACTIVE SUBSTANCE |
| US7037718B2 (en) | 2001-10-26 | 2006-05-02 | Cornell Research Foundation, Inc. | Mutant purine nucleoside phosphorylase proteins and cellular delivery thereof |
| CA2502109C (en) * | 2004-03-24 | 2010-02-23 | Yamasa Corporation | 4'-c-substituted-2-haloadenosine derivative |
| CN100532388C (zh) | 2007-07-16 | 2009-08-26 | 郑州大学 | 2’-氟-4’-取代-核苷类似物、其制备方法及应用 |
| US20090318380A1 (en) | 2007-11-20 | 2009-12-24 | Pharmasset, Inc. | 2',4'-substituted nucleosides as antiviral agents |
| WO2011005860A2 (en) | 2009-07-07 | 2011-01-13 | Alnylam Pharmaceuticals, Inc. | 5' phosphate mimics |
| US9198972B2 (en) | 2010-01-28 | 2015-12-01 | Alnylam Pharmaceuticals, Inc. | Monomers and oligonucleotides comprising cycloaddition adduct(s) |
| WO2011133871A2 (en) | 2010-04-22 | 2011-10-27 | Alnylam Pharmaceuticals, Inc. | 5'-end derivatives |
| EP2619215B1 (en) | 2010-09-22 | 2018-09-05 | Alios Biopharma, Inc. | Azido nucleosides and nucleotide analogs |
| AR088262A1 (es) | 2011-10-06 | 2014-05-21 | Dow Agrosciences Llc | Moleculas de acido nucleico que se dirigen a rpa70 y confieren resistencia a plagas de coleopteros |
| SG10201913554YA (en) | 2011-12-22 | 2020-03-30 | Alios Biopharma Inc | Substituted nucleosides, nucleotides and analogs thereof |
| GEP201706721B (en) | 2012-03-21 | 2017-08-25 | Alios Biopharma Inc | Substituted nucleosides, nucleotides and analogs thereof |
| US9441007B2 (en) | 2012-03-21 | 2016-09-13 | Alios Biopharma, Inc. | Substituted nucleosides, nucleotides and analogs thereof |
| AU2014302711A1 (en) | 2013-06-26 | 2015-12-10 | Alios Biopharma, Inc. | Substituted nucleosides, nucleotides and analogs thereof |
| WO2015054465A1 (en) | 2013-10-11 | 2015-04-16 | Alios Biopharma, Inc. | Substituted nucleosides, nucleotides and analogs thereof |
| WO2015143712A1 (en) | 2014-03-28 | 2015-10-01 | Merck Sharp & Dohme Corp. | 4'-substituted nucleoside reverse transcriptase inhibitors |
| MA40031A (fr) | 2014-06-24 | 2015-12-30 | Alios Biopharma Inc | Nucléosides substitués, nucléotides et analogues de ceux-ci |
| HUE051986T2 (hu) | 2014-06-24 | 2021-04-28 | Janssen Biopharma Inc | Helyettesített nukleozidok, nukleotidek és analógjaik virális fertõzés kezelésére való alkalmazásra |
| WO2016057866A1 (en) | 2014-10-09 | 2016-04-14 | Board Of Regents Of The University Of Nebraska | Compositions and methods for the delivery of therapeutics |
| CA2965719A1 (en) * | 2014-10-31 | 2016-05-06 | Sandoz Ag | Improved fluorination process |
| MA41213A (fr) | 2014-12-19 | 2017-10-24 | Alios Biopharma Inc | Nucléosides substitués, nucléotides et analogues de ceux-ci |
| MX391226B (es) * | 2015-09-23 | 2025-03-21 | Merck Sharp & Dohme Llc | Inhibidores de transcriptasa inversa de nucleosido 4'-substituido y preparaciones de los mismos. |
| JOP20170038B1 (ar) * | 2016-02-12 | 2021-08-17 | Merck Sharp & Dohme | مركبات للاستخدام لعلاج عدوى بفيروس hiv والوقاية منه |
| US11117904B2 (en) | 2016-06-23 | 2021-09-14 | Viiv Healthcare Company | Compositions and methods for the delivery of therapeutics |
| US11021510B2 (en) | 2016-11-03 | 2021-06-01 | Laurence I. Wu | Prodrugs of clofarabine |
| US20190185508A1 (en) | 2017-12-15 | 2019-06-20 | Merck Sharp & Dohme Corp. | Deuterated nucleoside reverse transcriptase inhibitors |
| EP3762396A1 (en) * | 2018-03-07 | 2021-01-13 | GlaxoSmithKline Intellectual Property (No.2) Limited | Compounds useful in hiv therapy |
| SG11202009906TA (en) | 2018-04-09 | 2020-11-27 | Eisai R&D Man Co Ltd | Pladienolide compounds and their use |
| AU2019317810A1 (en) | 2018-08-09 | 2021-02-25 | Glaxosmithkline Intellectual Property (No.2) Limited | Compounds useful in HIV therapy |
| JP2021536444A (ja) | 2018-08-30 | 2021-12-27 | グラクソスミスクライン、インテレクチュアル、プロパティー、(ナンバー2)、リミテッドGlaxosmithkline Intellectual Property (No.2) Limited | Ｈｉｖ療法に有用な化合物 |
| US12018435B2 (en) | 2019-03-06 | 2024-06-25 | Chemstone, Inc. | Liquid dispersions for acyl halides |
-
2020
- 2020-03-04 CN CN202080030422.7A patent/CN113811360A/zh active Pending
- 2020-03-04 CA CA3132112A patent/CA3132112A1/en active Pending
- 2020-03-04 SG SG11202109253SA patent/SG11202109253SA/en unknown
- 2020-03-04 JP JP2021552772A patent/JP2022525013A/ja not_active Ceased
- 2020-03-04 CR CR20210460A patent/CR20210460A/es unknown
- 2020-03-04 TW TW109107136A patent/TW202102233A/zh unknown
- 2020-03-04 BR BR112021017604A patent/BR112021017604A2/pt not_active IP Right Cessation
- 2020-03-04 PH PH1/2021/500034A patent/PH12021500034A1/en unknown
- 2020-03-04 KR KR1020217031465A patent/KR20210136052A/ko not_active Withdrawn
- 2020-03-04 MX MX2021010700A patent/MX2021010700A/es unknown
- 2020-03-04 EA EA202192433A patent/EA202192433A1/ru unknown
- 2020-03-04 PE PE2021001461A patent/PE20212089A1/es unknown
- 2020-03-04 AR ARP200100588A patent/AR118240A1/es not_active Application Discontinuation
- 2020-03-04 WO PCT/IB2020/051878 patent/WO2020178767A1/en not_active Ceased
- 2020-03-04 EP EP20712038.7A patent/EP3934760A1/en active Pending
- 2020-03-04 MA MA055200A patent/MA55200A/fr unknown
- 2020-03-04 AU AU2020231934A patent/AU2020231934B2/en not_active Ceased
- 2020-05-04 US US16/865,678 patent/US12240853B2/en active Active
-
2021
- 2021-06-01 US US17/335,145 patent/US20220411425A1/en not_active Abandoned
- 2021-08-24 ZA ZA2021/06096A patent/ZA202106096B/en unknown
- 2021-08-26 IL IL285894A patent/IL285894A/en unknown
- 2021-09-03 CL CL2021002309A patent/CL2021002309A1/es unknown
- 2021-09-24 CO CONC2021/0012579A patent/CO2021012579A2/es unknown
-
2023
- 2023-11-14 US US18/508,355 patent/US20240182473A1/en not_active Abandoned
-
2025
- 2025-02-12 US US19/051,307 patent/US20260035371A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022525013A5 (https=) | ||
| JP2010530376A5 (https=) | ||
| JP2013542247A5 (https=) | ||
| RU2013121788A (ru) | Ингибиторы репликации вич | |
| JP2016530259A5 (https=) | ||
| JP2018021046A5 (https=) | ||
| HRP20211543T1 (hr) | Derivati kinazolina koji se koriste za liječenje hiv-a | |
| JP2016508134A5 (https=) | ||
| JP2017057230A5 (https=) | ||
| RU2015131006A (ru) | ЗАМЕЩЕННОЕ ПРОИЗВОДНОЕ СПИРОПИРИДО[1,2-a]ПИРАЗИНА И ЕГО ПРИМЕНЕНИЕ В МЕДИЦИНЕ В КАЧЕСТВЕ ИНГИБИТОРА ИНТЕГРАЗЫ ВИРУСА ИММУНОДЕФИЦИТА ЧЕЛОВЕКА (ВИЧ) | |
| JP2009535352A5 (https=) | ||
| JP2015038149A5 (https=) | ||
| JP2024540183A5 (https=) | ||
| JP2022537047A5 (https=) | ||
| JP2022505597A5 (https=) | ||
| RU2011127080A (ru) | Производное циклоспорина для применения в лечении заражения вирусом гепатита с и вич | |
| JP2011527299A5 (https=) | ||
| JP2022531251A5 (https=) | ||
| JP2017529830A5 (https=) | ||
| JP2015537009A5 (https=) | ||
| JP2021529829A5 (https=) | ||
| JP2020529995A5 (https=) | ||
| RU2019112148A (ru) | Фармацевтическая композиция и способ лечения неалкогольной жировой болезни печени | |
| FI3506900T3 (fi) | Ampreloksetiini käytettäväksi neurogeenisen ortostaattisen hypotension | |
| FI3528791T3 (fi) | Dispergoituvia koostumuksia |